Madrigal Pharmaceuticals has entered into an exclusive global licensing agreement with CSPC Pharmaceutical Group for SYH2086, a preclinical oral small molecule GLP-1 receptor agonist derived from orforglipron.
Madrigal Pharmaceuticals 已与石药集团达成了一项关于 SYH2086 的全球独家许可协议，SYH2086 是一种源自 orforglipron 的临床前口服小分子 GLP-1 受体激动剂。
Metabolic dysfunction-associated steatohepatitis (MASH), previously referred to as nonalcoholic steatohepatitis (NASH), is a progressive liver disease that can lead to serious complications such as cirrhosis, liver failure, liver cancer, and premature death. It is currently the primary cause of liver transplantation in women and the second most common reason overall in the United States.
代谢功能障碍相关脂肪性肝炎（MASH），以前称为非酒精性脂肪性肝炎（NASH），是一种进展性肝病，可能导致严重并发症，如肝硬化、肝衰竭、肝癌和早逝。目前，它是女性肝移植的主要原因，在美国也是总体上第二大常见原因。
In Europe, MASH is the fastest-growing cause of liver transplant procedures..
在欧洲，MASH 是肝移植手术增长最快的原因。
The compound is currently in the early stages of development, and Madrigal aims to begin clinical trials in the first half of 2026.
该化合物目前处于开发的早期阶段，Madrigal 计划在 2026 年上半年开始临床试验。
The agreement supports Madrigal’s strategy to strengthen its pipeline in metabolic dysfunction-associated steatohepatitis (MASH). The company sees potential in combining SYH2086 with its approved drug, Rezdiffra, to create a once-daily oral treatment that addresses both weight reduction and liver health. .
该协议支持了Madrigal加强其在代谢功能障碍相关脂肪性肝炎（MASH）领域产品线的战略。该公司认为，将SYH2086与其已获批药物Rezdiffra结合使用，有望开发出一种每日一次的口服疗法，同时解决体重减轻和肝脏健康问题。
In previous trials, modest weight loss has been shown to improve the antifibrotic effect of Rezdiffra, suggesting that combining the two treatments could enhance outcomes for MASH patients.
在之前的试验中，适度的体重减轻已被证明可以增强Rezdiffra的抗纤维化效果，这表明将这两种治疗方法结合使用可能会改善MASH患者的治疗效果。
CSPC expressed confidence in Madrigal’s ability to advance SYH2086 through development and deliver benefits to patients globally.
石药集团表示，相信Madrigal公司有能力推动SYH2086的研发，并为全球患者带来益处。
Source: madrigalpharma.com
来源：madrigalpharma.com